FGF9, a potent mitogen, is a new ligand for integrin αvβ3, and the FGF9 mutant defective in integrin binding acts as an antagonist.
C.-C. Chang, Y. K. Takada, C.-W. Cheng, Y. Maekawa, S. Mori, y. takada
This study identifies FGF9 as a new ligand for integrin αvβ3 and shows that a mutant defective in integrin binding acts as an antagonist by suppressing FGF9 signaling.
Cells · Feb 7, 2024Peer-reviewedBiochemistry